Previous
Laboratory tests show Sambucol® neutralises Common and Avian Flu Virus H5N1
Added: (Thu Jan 19 2006)
New research, carried out by Retroscreen Virology has indicated that
Sambucol®, a patented formula, may fight the virulent Avian Flu virus. Results have been presented yesterday, Wednesday, in a press conference held in the Royal Society of Medicine, London. Speakers included Prof. Hannoun, Emeritus Professor at the Pasteur Institute and Dr. Mumcuoglu, developer of Sambucol®.
Laboratory trials held in a leading research institute, Retroscreen Virology
Ltd, associated with the University of London found Sambucol® to be at least
99% effective against the Avian Flu virus H5N1. Sambucol® was effective at
significantly neutralising the infectivity of the virus in cell cultures. These
results will also be presented during the International Conference on Bird Flu:
“The First Pandemic of the 21st Century. A Central Role for Antivirals”, to be
held at St. Bartholomew’s Hospital on January 19th-20th 2006.
Dr. Madeleine Mumcuoglu, is looking into further investigations into the
activity of Sambucol® against Avian Flu on a wider scale.
In an earlier study (1995) Sambucol® was found to be effective against a wide range of influenza strains. Laboratory studies conducted at the Hebrew
University – Hadassah Medical School, Jerusalem demonstrated the activity
of Sambucol® against human, swine, and avian influenza strains.
Sambucol®'s efficacy was also demonstrated in two double blind, placebo
controlled clinical studies. Sambucol® was shown to cut the duration and
severity of the common flu by up to half.
ENDS
Notes to editors;
Sambucol® is based on an active substance isolated from the black elderberry.
Manufactured by Razei Bar Industries Israel, Sambucol® is available in 17
countries and in the UK is sold in Tesco, leading chemists, independent health
food stores and wholesalers from £8.49.
For photography please visit the following site and enter the log in details:
FTP address: ftp://pixelit.co.il
user name: ftp_razeibar
password: 63+84675
For further press information please contact: Francesca Gaffey/Cheryl Davies,
Communique Public Relations, Waterside, No2 Canal Street, Manchester, M1
3HE. Tel: 0161 242 5120/0161 242 5108 Fax: 0161 228 7391 E-mail:
francesca.gaffey@communiquepr.co.uk cheryl.davies@communiquepr.co.uk
For research information please visit: Retroscreen Virology Ltd. at:
http://www.retroscreen.com/
For product information please visit:
Razei Bar Industries (1996) Ltd. At: www.sambucol.com